about
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic miceNew target antigens for cancer immunopreventionVaccines for tumour preventionCancer immunopreventionMultiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitorAntimetastatic Activity of a Preventive Cancer VaccineIntratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cellsCytokine gene therapy: hopes and pitfalls.Modeling the competition between lung metastases and the immune system using agents.The prospects for cancer gene therapy.In silico modeling and in vivo efficacy of cancer-preventive vaccinations.CD99 acts as an oncosuppressor in osteosarcomaPreclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.Immunoprevention of colorectal cancer: a future possibility?Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.Preclinical HER-2 Vaccines: From Rodent to Human HER-2Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.Molecular and cellular biology of rhabdomyosarcoma.Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.Vaccines and other immunological approaches for cancer immunoprevention.Rethinking herpes simplex virus: the way to oncolytic agents.The molecular basis of herpesviruses as oncolytic agents.Preclinical vaccines against mammary carcinoma.Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells.Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment.Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function.Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma.Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role.Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma.Immunological prevention of a multigene cancer syndrome.Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells.Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity.Murine model for skeletal metastases of Ewing's sarcoma.Concomitant amplification and expression of PAX7-FKHR and MYCN in a human rhabdomyosarcoma cell line carrying a cryptic t(1;13)(p36;q14).Production of stem cell factor and expression of c-kit in human rhabdomyosarcoma cells: lack of autocrine growth modulation.
P50
Q24670549-7818DE60-F06A-4DD4-863B-F1126418FDF5Q28250549-23AE29B5-0CEE-4713-838E-091ED65E4891Q28299036-F71C0DD3-BDD0-493A-AD2F-7099235E95CCQ28303393-3C74D4D3-9161-4BA9-97A2-167277FDB792Q28728165-6B75DD73-8EA9-4028-88D3-C2E02B41375EQ29399455-ACCD74C6-C9CE-44FD-9E3D-24C70B6BB3FFQ33645792-861389D7-02D9-4218-BC36-35330CB2736DQ33650945-F17885CF-D9A2-4723-BBBB-9CBDCFEFB849Q33755575-34EA9812-B595-4BBB-AD8F-D6DA75B577AEQ34117982-2085416E-DA6E-4796-96CA-714D659B7323Q34141954-F45BC64E-CDDF-4AC6-9AA9-CC25964B8C2BQ34483649-F452940E-5C38-4243-9FE4-378359B5BA33Q34574879-0D1596E6-C42A-47F4-9738-C89F461FD8C0Q35029033-82F7C926-7DD0-4376-84D4-DDA4DCF0874CQ36401520-2F0C6DC9-513C-4BF1-88C4-97813AA314B4Q36914661-45318DE8-0353-493E-9E0E-D16DF4D0F7D4Q37198935-0B083D00-B104-4EEE-BECD-62D7769FC6ACQ37630588-48E97ED5-9073-4854-A234-3C7BE7424F2BQ37691212-994195FE-613A-4A96-A819-D22381C2E568Q37821015-39F6AE79-8F29-474F-8454-6C251675AEB0Q37882608-82ABD6DB-6C22-4A07-BC49-6999BC945A4FQ37899225-B3E01CED-CDBE-4ABC-AE11-657B3B110E74Q38160252-38D53977-2ADB-4973-821E-41C503F671C7Q38295459-C1E67247-745C-417A-A435-D262A3FA1FD0Q38962338-2DD2918E-C468-4CFE-9265-1CB3B7290185Q39069971-EE4521A2-9273-4BFB-BEAF-060778EB7E5EQ39289206-CD3F2F81-CE1A-43C0-99CE-99A7BCA306AEQ39488320-582FD601-EB12-4841-B275-069249A9F4BBQ39642376-C794FD5B-52E9-4709-B7D8-E8B4AA0B1C79Q40172818-BD6071E1-9AD8-4214-A57F-90EBF71EAD6EQ40240048-177926E6-53E8-4D19-87B2-6EC0E88AEB2BQ40298751-5F6A8AC2-CD18-4006-9FA0-C46FABFBC1FDQ40324701-96437516-2D44-4813-B782-D75FD7B33E30Q40344079-9D097534-A203-4F74-8718-F66B4FE15D52Q40490598-CA920234-7235-4FEA-ACF2-8016D4696378Q40583180-EF7B879F-05C5-47E1-AFA7-DE9D065C37D5Q40594474-A24EC8BA-4B58-4C36-9064-273F086E78A4Q40725641-D5B68000-2EE1-4AD6-A1BC-55117B14C012Q40844263-8B778157-7BBE-42D5-AB86-BDC0423BEA06Q40997946-83A30471-4EC5-4985-9BC2-2EFC699734B6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Patrizia Nanni
@ast
Patrizia Nanni
@en
Patrizia Nanni
@es
Patrizia Nanni
@nl
Patrizia Nanni
@sl
type
label
Patrizia Nanni
@ast
Patrizia Nanni
@en
Patrizia Nanni
@es
Patrizia Nanni
@nl
Patrizia Nanni
@sl
prefLabel
Patrizia Nanni
@ast
Patrizia Nanni
@en
Patrizia Nanni
@es
Patrizia Nanni
@nl
Patrizia Nanni
@sl
P106
P1153
7007130215
P21
P31
P496
0000-0001-5319-0803